Patents by Inventor Michelle Campbell
Michelle Campbell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11928095Abstract: Example embodiments relate to a system to generate and cause display of a specially configured graphical user interface to receive and present collections of images. According to certain example embodiments, an image analysis system: receives an image file from a client device; generates a hash value based on the image file; performs a comparison of the hash value with a list that comprises a collection of hash values; identifies a match to the hash value among the collection of hash values; assigns a label to the image file in response to identifying the match among the collection of image files from the list; and indexes the image file at a memory location identified by the label assigned to the image file.Type: GrantFiled: September 9, 2022Date of Patent: March 12, 2024Assignee: Palantir Technologies Inc.Inventors: Michael Stein, Adam Campbell, Alicia Monfre, Angela Muller, Enoch Hsiao, Lucas Ray, Matthew Brady, Michelle Brown, Paul Lisker
-
Publication number: 20220098296Abstract: IL-18 participates in both innate and acquired immunity. The bioactivity of IL-18 is negatively regulated by the IL-18 binding protein (IL18BP), a naturally occurring and highly specific inhibitor. This soluble protein forms a complex with free IL-18 preventing its interaction with the IL-18 receptor, thus neutralizing and inhibiting its biological activity. The present invention discloses binding molecules, in particular antibodies or fragments thereof, which bind IL-18 and do not bind IL-18 bound to IL-18BP (IL-18/IL-18BP complex). Apart from its physiological role, IL-18 has been shown to mediate a variety of autoimmune and inflammatory diseases. The binding molecules of the inventions may be used as therapeutic molecules for treating IL-18-related autoimmune and inflammatory diseases or as diagnostic tools for characterizing, detecting and/or measuring IL-18 not bound to IL-18BP as component of the total IL-18 pool.Type: ApplicationFiled: July 27, 2021Publication date: March 31, 2022Inventors: Michael Otto BARDROFF, Barbara BRANNETTI, Emma Michelle CAMPBELL, Beate DIEFENBACH-STREIBER, Adina EBERTH, Christian Carsten Silverster KUNZ, Sylwia MARSHALL, Jean-Michel Rene RONDEAU, Jean-Marc Alfred SCHLAEPPI, Gino Anselmus VAN HEEKE
-
Patent number: 11111293Abstract: Interleukin-18 (IL-18) participates in both innate and acquired immunity. The bioactivity of IL-18 is negatively regulated by the IL-18 binding protein (IL18BP), a naturally occurring and highly specific inhibitor. This soluble protein forms a complex with free IL-18 preventing its interaction with the IL-18 receptor, thus neutralizing and inhibiting its biological activity. The present invention discloses binding molecules, in particular antibodies or fragments thereof, which bind IL-18 and do not bind IL-18 bound to IL-18BP (IL-18/IL-18BP complex). Apart from its physiological role, IL-18 has been shown to mediate a variety of autoimmune and inflammatory diseases. The binding molecules of the inventions may be used as therapeutic molecules for treating IL-18-related autoimmune and inflammatory diseases or as diagnostic tools for characterizing, detecting and/or measuring IL-18 not bound to IL-18BP as component of the total IL-18 pool.Type: GrantFiled: August 24, 2018Date of Patent: September 7, 2021Assignee: NOVARTIS AGInventors: Michael Otto Bardroff, Barbara Brannetti, Emma Michelle Campbell, Beate Diefenbach-Streiber, Adina Eberth, Christian Carsten Silverster Kunz, Sylwia Marshall, Jean-Michel Rene Rondeau, Jean-Marc Alfred Schlaeppi, Gino Anselmus Van Heeke
-
Patent number: 10683471Abstract: A neutral or acidic automatic dishwashing detergent composition including inorganic bleach, enzymes and a cleaning agent selected from the group consisting of cleaning surfactants, soil suspending polymers and mixtures thereof and from 0.01% to 5% by weight of the composition of a perfume and wherein the composition has a cleaning index of at least 60 and a care index of at least 4 as defined herein.Type: GrantFiled: November 30, 2016Date of Patent: June 16, 2020Assignee: The Procter & Gamble CompanyInventors: Philip Frank Souter, Alan Thomas Brooker, Lindsay Suzanne Bewick, Lynn Michelle Campbell
-
Publication number: 20190085068Abstract: IL-18 participates in both innate and acquired immunity. The bioactivity of IL-18 is negatively regulated by the IL-18 binding protein (IL18BP), a naturally occurring and highly specific inhibitor. This soluble protein forms a complex with free IL-18 preventing its interaction with the IL-18 receptor, thus neutralizing and inhibiting its biological activity. The present invention discloses binding molecules, in particular antibodies or fragments thereof, which bind IL-18 and do not bind IL-18 bound to IL-18BP (IL-18/IL-18BP complex). Apart from its physiological role, IL-18 has been shown to mediate a variety of autoimmune and inflammatory diseases. The binding molecules of the inventions may be used as therapeutic molecules for treating IL-18-related autoimmune and inflammatory diseases or as diagnostic tools for characterizing, detecting and/or measuring IL-18 not bound to IL-18BP as component of the total IL-18 pool.Type: ApplicationFiled: August 24, 2018Publication date: March 21, 2019Applicant: NOVARTIS AGInventors: Michael Otto BARDROFF, Barbara BRANNETTI, Emma Michelle CAMPBELL, Beate DIEFENBACH-STREIBER, Adina EBERTH, Christian Carsten Silverster KUNZ, Sylwia MARSHALL, Jean-Michel Rene RONDEAU, Jean-Marc Alfred SCHLAEPPI, Gino Anselmus VAN HEEKE
-
Patent number: 10081677Abstract: Interleukin-18 (IL-18) participates in both innate and acquired immunity. The bioactivity of IL-18 is negatively regulated by the IL-18 binding protein (IL18BP), a naturally occurring and highly specific inhibitor. This soluble protein forms a complex with free IL-18 preventing its interaction with the IL-18 receptor, thus neutralizing and inhibiting its biological activity. The present invention discloses binding molecules, in particular antibodies or fragments thereof, which bind IL-18 and do not bind IL-18 bound to IL-18BP (IL-18/IL-18BP complex). Apart from its physiological role, IL-18 has been shown to mediate a variety of autoimmune and inflammatory diseases. The binding molecules of the inventions may be used as therapeutic molecules for treating IL-18-related autoimmune and inflammatory diseases or as diagnostic tools for characterizing, detecting and/or measuring IL-18 not bound to IL-18BP as component of the total IL-18 pool.Type: GrantFiled: May 25, 2016Date of Patent: September 25, 2018Assignee: NOVARTIS AGInventors: Michael Otto Bardroff, Barbara Brannetti, Emma Michelle Campbell, Beate Diefenbach-Streiber, Adina Eberth, Christian Carsten Silverster Kunz, Sylwia Marshall, Jean-Michel Rene Rondeau, Jean-Marc Alfred Schlaeppi, Gino Anselmus Van Heeke
-
Publication number: 20170175044Abstract: A neutral or acidic automatic dishwashing detergent composition including inorganic bleach, enzymes and a cleaning agent selected from the group consisting of cleaning surfactants, soil suspending polymers and mixtures thereof and from 0.01% to 5% by weight of the composition of a perfume and wherein the composition has a cleaning index of at least 60 and a care index of at least 4 as defined herein.Type: ApplicationFiled: November 30, 2016Publication date: June 22, 2017Inventors: Philip Frank SOUTER, Alan Thomas BROOKER, Lindsay Suzanne BEWICK, Lynn Michelle CAMPBELL
-
Patent number: 9650438Abstract: The present invention relates to human anti-IL-13 binding molecules, particularly antibodies, and to methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, such as asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.Type: GrantFiled: February 24, 2015Date of Patent: May 16, 2017Assignee: Novartis AGInventors: Emma Michelle Campbell, Sofia Parveen, Joe Buechler, Gunars Valkirs
-
Publication number: 20170101467Abstract: The present invention relates to human anti-IL-13 binding molecules, particularly antibodies, and to methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, such as asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.Type: ApplicationFiled: February 24, 2015Publication date: April 13, 2017Applicant: Novartis AGInventors: Emma Michelle Campbell, Sofia Parveen, Joe Buechler, Gunars Valkirs
-
Publication number: 20160376361Abstract: IL-18 participates in both innate and acquired immunity. The bioactivity of IL-18 is negatively regulated by the IL-18 binding protein (IL18BP), a naturally occurring and highly specific inhibitor. This soluble protein forms a complex with free IL-18 preventing its interaction with the IL-18 receptor, thus neutralizing and inhibiting its biological activity. The present invention discloses binding molecules, in particular antibodies or fragments thereof, which bind IL-18 and do not bind IL-18 bound to IL-18BP (IL-18/IL-18BP complex). Apart from its physiological role, IL-18 has been shown to mediate a variety of autoimmune and inflammatory diseases. The binding molecules of the inventions may be used as therapeutic molecules for treating IL-18-related autoimmune and inflammatory diseases or as diagnostic tools for characterizing, detecting and/or measuring IL-18 not bound to IL-18BP as component of the total IL-18 pool.Type: ApplicationFiled: May 25, 2016Publication date: December 29, 2016Applicant: NOVARTIS AGInventors: Michael Otto Bardroff, Barbara Brannetti, Emma Michelle Campbell, Beate Diefenbach-Streiber, Adina Eberth, Christian Carsten Silverster Kunz, Sylwia Marshall, Jean-Michel Rene Rondeau, Jean-Marc Alfred Schlaeppi, Gino Anselmus Van Heeke
-
Patent number: 9376489Abstract: Interleukin 18 (IL-18) participates in both innate and acquired immunity. The bioactivity of IL-18 is negatively regulated by the IL-18 binding protein (IL18BP), a naturally occurring and highly specific inhibitor. This soluble protein forms a complex with free IL-18 preventing its interaction with the IL-18 receptor, thus neutralizing and inhibiting its biological activity. The present invention discloses binding molecules, in particular antibodies or fragments thereof, which bind IL-18 and do not bind IL-18 bound to IL-18BP (IL-18/IL-18BP complex). Apart from its physiological role, IL-18 has been shown to mediate a variety of autoimmune and inflammatory diseases. The binding molecules of the inventions may be used as therapeutic molecules for treating IL-18-related autoimmune and inflammatory diseases or as diagnostic tools for characterizing, detecting and/or measuring IL-18 not bound to IL-18BP as component of the total IL-18 pool.Type: GrantFiled: September 4, 2013Date of Patent: June 28, 2016Assignee: Novartis AGInventors: Michael Otto Bardroff, Barbara Brannetti, Emma Michelle Campbell, Beate Diefenbach-Streiber, Adina Eberth, Christian Carsten Silvester Kunz, Sylwia Marshall, Jean-Michel Rene Rondeau, Jean-Marc Alfred Schlaeppi, Gino Anselmus Van Heeke
-
Patent number: D966484Type: GrantFiled: June 5, 2020Date of Patent: October 11, 2022Assignee: DSS PureAir, Inc.Inventors: Neil J. Campbell, Iyam Lynch, Michelle Campbell
-
Patent number: D967380Type: GrantFiled: June 5, 2020Date of Patent: October 18, 2022Assignee: DSS PureAir, Inc.Inventors: Neil Campbell, Iyam Lynch, Michelle Campbell
-
Patent number: D967381Type: GrantFiled: June 5, 2020Date of Patent: October 18, 2022Assignee: DSS PureAir, Inc.Inventors: Neil J. Campbell, Iyam Lynch, Michelle Campbell
-
Patent number: D967382Type: GrantFiled: June 5, 2020Date of Patent: October 18, 2022Assignee: DSS PureAir, Inc.Inventors: Neil J. Campbell, Iyam Lynch, Michelle Campbell
-
Patent number: D967383Type: GrantFiled: June 5, 2020Date of Patent: October 18, 2022Assignee: DSS PureAir, Inc.Inventors: Neil J. Campbell, Iyam Lynch, Michelle Campbell
-
Patent number: D979032Type: GrantFiled: October 17, 2022Date of Patent: February 21, 2023Assignee: DSS, Inc.Inventors: Neil J. Campbell, Iyam Lynch, Michelle Campbell
-
Patent number: D1010088Type: GrantFiled: October 7, 2022Date of Patent: January 2, 2024Assignee: DSS PureAir, IncInventors: Neil J. Campbell, Iyam Lynch, Michelle Campbell
-
Patent number: D1010089Type: GrantFiled: October 17, 2022Date of Patent: January 2, 2024Assignee: DSS PureAir, Inc.Inventors: Neil Campbell, Iyam Lynch, Michelle Campbell
-
Patent number: D1010090Type: GrantFiled: October 17, 2022Date of Patent: January 2, 2024Assignee: DSS PureAir, LLCInventors: Neil J. Campbell, Iyam Lynch, Michelle Campbell